Endocrine-Related Cancer current issue cover
Current Issue
Endocrine-Related Cancer, the flagship cancer journal of Society for Endocrinology
Submit your manuscript Author guidelines Journal scope Open access Publication charges Review for Endocrine-Related Cancer
 
Endocrine-Related Cancer key journal metrics
 
Latest Impact Factor: 3.9
Average time to first response: 13 days
 

 

EDITOR-IN-CHIEF

photograph of Professor Matthew Ringel
 
Matthew Ringel MD, PhD
Ralph W. Kurtz Professor of Medicine,
and Director of the Division of Endocrinology and Metabolism
The Ohio State University,
OH, USA

 

DEPUTY EDITOR

photograph of Professor Márta Korbonits
 
Márta Korbonits MD, PhD
Professor of Endocrinology and Metabolism,
William Harvey Research Institute,
Barts and the London School of Medicine,
Queen Mary University of London, UK
 
Meet the full editorial board
 
Apply to be an early career editor advert

 

 
Endocrine Oncology submit advert

 

Endocrine-Related Cancer advances and future directions in phaeochromocytoma and paraganglioma collection

 

Growth hormone in endocrine cancer collection advert

 

Endocrine-Related Cancer sign up for alerts advert
 

 

Endocrine-Related Cancer, a high-impact journal owned by the Society for Endocrinology linking hormones and cancer

 

Read the top 10 most cited articles published in 2022

 

The role of vitamin D in breast cancer risk and progression
Authors: Justine Vanhevel et al., Volume 29: Issue 2, Pages: R33–R55

 

Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review
Authors: Mirela Diana Ilie et al., Volume 29: Issue 7, Pages: 415–426

 

Advanced RAI-refractory thyroid cancer: an update on treatment perspectives
Authors: Olga Karapanou et al., Volume 29: Issue 5, Pages: R57–R66

 

Androgen receptor mutations for precision medicine in prostate cancer
Authors: Masaki Shiota, Volume 29: Issue 10, Pages: R143–R155

 

Improved pasireotide response in USP8 mutant corticotroph tumours in vitro
Authors: Adriana Albani et al., Volume 29: Issue 8, Pages: 503–511

 

Translating the immune microenvironment of thyroid cancer into clinical practice
Authors: Lucas Leite Cunha and Laura Sterian Ward, Volume 29: Issue 6, Pages: R67–R83

 

Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine
Authors: Susan Richter et al., Volume 29: Issue 4, Pages: 213–224

 

Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial
Authors: Cindy H Chau et al., Volume 29: Issue 2, Pages: 99–109

 

Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline
Authors: Sasha R Howard et al., Volume 29: Issue 11, Pages: G1–G33

 

Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures
Authors: Katharina Wang et al., Volume 29: Issue 6, Pages: 285–306

 
 
 

Editor's Choice

 

Read our Editor’s favourite articles published in 2022, chosen for their compelling content, originality and quality.

 

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Authors: Andreas Venizelos et al., Volume 29: Issue 1, Pages: 1–14

Inhibition of GATA2 in prostate cancer by a clinically available small molecule
Authors: Salma Kaochar et al., Volume 29: Issue 1, Pages: 15–31

Improved pasireotide response in USP8 mutant corticotroph tumours in vitro
Authors: Adriana Albani et al., Volume 29: Issue 8, Pages: 503–511

SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway
Authors: Chi-Yu Kuo et al., Volume 29: Issue 2, Pages: 47–58

Preclinical evaluation of targeted therapies in Sdhb-mutated tumors
Authors: Sophie Moog et al., Volume 29: Issue 6, Pages: R33–R55

Exploring stem cell biology in pituitary tumors and derived organoids
Authors: Charlotte Nys et al., Volume 29: Issue 2, Pages: R33–R55

Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors
Authors: Olga Lakiza et al., Volume 29: Issue 2, Pages: 375–388

Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations
Authors: Esra Karslioglu French et al., Volume 29: Issue 8, Pages: 467–473

The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings
Authors: Daniela Regazzo et al., Volume 29: Issue 5, Pages: 273–284

The effects of exercise and diet on sex steroids in breast cancer survivors
Authors: Justin C Brown et al., Volume 29: Issue 8, Pages: 485–493

Association of DNA methylation with steroidogenic enzymes in Cushing's adenoma
Authors: Takaya Kodama et al., Volume 29: Issue 8, Pages: 495–502

DNA methylation is a comprehensive marker for pediatric adrenocortical tumors
Authors: Ana Carolina Bueno et al., Volume 29: Issue 11, Pages: 599–613